Mid Cap Pharma Company Fixes Record Date For Split Of Shares, Rises 714% In 5-Yrs

Mid cap company operating in pharmaceuticals sector, J.B. Chemicals & Pharmaceuticals is set to carry out stock split soon after board of directors fixed record date for sub-division of shares. The record date for stock split is September 18, 2023. J.B. Chemicals & Pharmaceuticals shares fell 2.47% in last 1-week, rallied 42% in last 6-months, and gained 714% in last 5-years. Check details below:

J.B. Chemicals & Pharmaceuticals Sets Record Date For Sub-Division of Shares: According to the BSE filing of the company dated August 29, "Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed September 18, 2023 as record date, to ascertain eligibility of the beneficial owners/shareholders of the Company for the purpose of Split/ SubDivision of 1 equity share of Rs. 2/- each into 2 equity shares of Re. 1/- each."

J.B.Chemicals & Pharmaceuticals Stock Performance & Return: Last trading price of J.B. Chemicals & Pharmaceuticals share is Rs 2744.50 apiece with intraday fall of 3.74%. Its 52-week high price is Rs 2935.00 apiece and 52-week low price is Rs 1758.60 apiece, respectively. J.B. Chemicals & Pharmaceuticals has a market capitalisation of 21,260.00 crore. J.B. Chemicals & Pharmaceuticals stock rallied 39% YTD, surged 55% in last 1-year, gained 61% in last 2-years, and offered its shareholders return of 243% in last 5-years.

J.B. Chemicals & Pharmaceuticals Financials: The mid cap company for the quarter ended June 30, 2023 announced a surge of 17.59% in its consolidated total income to Rs 901.83 crore as against its last quarter total income of Rs 766.90 crore. The company announced its recent quarter net profit after tax at Rs 142.32 crore.

J.B. Chemicals & Pharmaceuticals About: The pharmaceutical company has varied products and dosage forms across therapeutic categories. While it is a big player in gastroenterology, hypertension, and dermatology, It has also entered newer therapeutic categories like nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy (NRT), according to its official website.

Disclaimer

The stock just highlights the stock split and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.